EP3468474A1 - Procede de mesure du debit cardiaque par echographie - Google Patents
Procede de mesure du debit cardiaque par echographieInfo
- Publication number
- EP3468474A1 EP3468474A1 EP17727897.5A EP17727897A EP3468474A1 EP 3468474 A1 EP3468474 A1 EP 3468474A1 EP 17727897 A EP17727897 A EP 17727897A EP 3468474 A1 EP3468474 A1 EP 3468474A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cardiac output
- images
- contrast
- signal
- zone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000747 cardiac effect Effects 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 47
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 27
- 210000005245 right atrium Anatomy 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 10
- 238000004590 computer program Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 238000000691 measurement method Methods 0.000 claims description 4
- 239000002872 contrast media Substances 0.000 abstract description 15
- 238000005259 measurement Methods 0.000 description 20
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 238000002592 echocardiography Methods 0.000 description 9
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 210000000709 aorta Anatomy 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000011325 microbead Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 4
- 238000013175 transesophageal echocardiography Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000002961 echo contrast media Substances 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010967 transthoracic echocardiography Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000035478 Interatrial communication Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 206010034476 Pericardial haemorrhage Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241001661807 Systole Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004491 foramen ovale Anatomy 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 201000002303 hemopericardium Diseases 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005293 physical law Methods 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000036593 pulmonary vascular resistance Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 238000013183 transoesophageal echocardiography Methods 0.000 description 1
- 229960003853 ultrasound contrast media Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/06—Measuring blood flow
- A61B8/065—Measuring blood flow to determine blood output from the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/46—Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient
- A61B8/461—Displaying means of special interest
- A61B8/463—Displaying means of special interest characterised by displaying multiple images or images and diagnostic data on one display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/52—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/5215—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data
- A61B8/5223—Devices using data or image processing specially adapted for diagnosis using ultrasonic, sonic or infrasonic waves involving processing of medical diagnostic data for extracting a diagnostic or physiological parameter from medical diagnostic data
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Definitions
- the present invention relates to the measurement of cardiac output.
- the cardiac output is the amount of blood ejected by the heart per minute, and is the product of the amount of blood ejected by the heart at each contraction, the stroke volume, by the heart rate. In people undergoing resuscitation or under anesthesia with hemodynamic instability and shock, this parameter should be carefully monitored. Different methods are used to measure cardiac output.
- thermodilution One of the main techniques is the so-called “thermodilution” method.
- a "Swan-Ganz” catheter is introduced from a large central vein and pushed into the right heart and then into the pulmonary artery. This catheter has exit apertures in the right atrium and the pulmonary artery.
- Low-inertia thermistors are present on the catheter to measure small changes in blood temperature.
- a bolus of cold liquid is injected through an orifice in the right atrium, cooling the blood a few tenths of a degree.
- a variation in temperature is recorded at the end of the catheter, and has the appearance shown in Figure 1. The knowledge of the variation in temperature can calculate the cardiac output.
- thermodilution techniques are invasive, since it is necessary to set up one or more intravascular catheters. Complications associated with such interventions are well known, including mechanical related to the difficulties of laying the catheter or catheters, such as the appearance of hematoma, pneumothorax or hemopericardium, as well as thromboembolic or infectious complications.
- Cardiac output can also be measured by Doppler echocardiography (DTE).
- DTE Doppler echocardiography
- the ED calculates the flow velocity in the heart accurately.
- the volume of systolic ejection can be calculated from two measurements: the diameter of the aorta D on the one hand and the time-velocity integral of the aortic flow VTIao recorded in pulsed Doppler.
- a certain amount of blood is ejected into the aorta at a given speed. This volume of blood travels in the aorta a distance that is calculable if we know the average speed and duration of ejection.
- the ED can measure this average speed and know the duration of ejection.
- This technique is non-invasive, relatively uncomplicated to implement and the measured flow is well correlated with the measurement of the flow by thermodilution.
- this technique can not be automated, and it is sometimes difficult to achieve transthoracic resuscitation because the echogenicity of the patient can be bad, that is to say, it is difficult to see the heart structures well.
- the flow rate being obtained from a measurement of the diameter of the aorta squared, any error, even minimal at this level, can lead to significant errors in the calculation of the flow.
- transthoracic echocardiography In cases where the heart can not be well visualized by transthoracic echocardiography, it is possible to use a probe that is placed in the esophagus. This technique is called transesophageal echocardiography. In the same way as by seeing transthoracic, it is possible to measure the diameter of the aorta and the flow in order to calculate the cardiac output.
- echocardiographic techniques are not automatable and are operator-dependent.
- some pathologies distort the measurement such as an abnormality of the aortic valve or the existence of an obstruction at the exit of the left ventricle.
- International application WO 95/29705 discloses a method for measuring cardiac output, using ultrasonic images and intravenous injection of a contrast medium comprising microbeads.
- the cardiac output is calculated by integrating a relationship between the time and the video density of the images obtained during the transit of the microbubbles as a function of the volume injected.
- Numerous scientific articles teach to measure certain cardiac parameters by injecting a contrast product comprising microbeads, using the images acquired by echocardiography during the dilution of the product.
- Yun et al's article “Usefulness of ultrasound contrast media for cardiac output measurement with echocardiography", Korean Journal of Veterinary Research, 2015, 55 (1): 47-52, uses scoring to segments of the area analyzed after injection of a contrast medium to improve visualization of areas of the heart, and uses a Simpson method to calculate cardiac output.
- the aim of the invention is to meet this need and, in one of its aspects, it achieves it by means of a method for measuring cardiac output using an ultrasound machine, in which process:
- a plurality of images of an area of the heart where a contrast medium has been injected is acquired by the ultrasound machine to, at different times,
- the cardiac output is calculated from the value given to at least one parameter of a reference function, adjusted so that said function best describes the evolution of the measured intensity values.
- intensity of the echography signal of the zone is meant information representative of the average gray level of the pixels on the image in the zone.
- the invention provides a minimally invasive, easily automatable and reproducible cardiac output measurement.
- the measurement can be reproduced, being non-dependent on an operator to perform measurements.
- the method according to the invention can be used during the anesthesia of a patient at risk of instability. In intensive care, it is used in all hemodynamically unstable patients.
- the invention makes use of the fact that the variation and the rate of disappearance of the contrast product is correlated with the cardiac output.
- the recording of the ultrasound signal related to the passage of microbubbles in the area of the heart observed thus obeys physical laws that contain the information of the flow rate of the blood carrying the microbubbles.
- the contrast medium is preferably a serum loaded with air microbubbles. Such a contrast product can be generated very easily and is completely absorbed in the body after the measurement.
- the method of measuring the cardiac output can thus be preceded by the step of injecting air microbubbles as a contrast product. This injection can take place automatically, at regular intervals. After each injection, cardiac output can also be measured automatically. An alarm can be generated if an abnormal cardiac output value is detected.
- This method can be implemented also on the animal, with the possible sacrifice of the animal.
- the method according to the invention is adapted to be implemented in real time, enabling the medical team to react as quickly as possible according to the calculated value of the cardiac output. It can be implemented automatically at regular intervals to monitor the patient's condition.
- the invention can be implemented by transthoracic or transesophageal echocardiography.
- the contrast medium is introduced through the right atrium via venous access.
- This access may be a jugular vein, located at the neck, or by the femoral vein where the contrast increases more slowly, or a peripheral vein.
- the invention also relates to a device for producing air microbubbles as a contrast medium, in particular for implementing the cardiac output measurement method according to the invention as defined above.
- the device comprising:
- the device for producing a contrast product according to the invention can be adapted to an existing ultrasound device or be part of an independent system.
- the contrast medium is preferably a sterile mixture of serum and air, containing in particular between 5 ml and 10 ml of saline and between 0.5 ml and 1 ml of air, for example 4 ml of serum and 0.5 ml. air.
- the valve can be controlled automatically in opening once the cycle of depressions and re-releases at ambient pressure is completed, for the injection of serum loaded with microbubbles of air.
- the air microbubbles formed by the mixture do not pass from the right ventricle to the left ventricle, being stopped by the lungs. Microbubbles have a short life cycle, making the presence of contrast medium ephemeral in the area of the heart where it is injected.
- the plurality of images of the area of the heart where the contrast product has been injected is acquired by the ultrasound machine, at different times, preferably by noting the time spacing between these images.
- the images can be saved in DICOM format (for "Digital Imaging and Communications in Medicine"), a standard for the computer management of data from medical imaging.
- DICOM format for "Digital Imaging and Communications in Medicine”
- the images are recorded in any possible export format, for example video.
- An MIP-type intermediate image for "Maximim Intensity Projection" can be created to evaluate the extent of contrast on the image.
- the region of interest of the heart zone can be determined manually or automatically, being transferred to all the images acquired temporally.
- the outline of the region of interest is for example circular, oval, polygonal, or other, and for example follows the morphology of the right cavities.
- the intensity of the signal is for example obtained by averaging the gray levels of the pixels of the image within this contour.
- a signal representing the growth and decay, over time, of intensity values of the observed area, extracted from the images can be obtained.
- the envelope of this signal is advantageously similar to the signal obtained by the known thermodilution technique.
- a formula identical to that used for thermodilution, applied to this signal in its entirety, can then be used to calculate the cardiac output.
- a signal representing only the decay, over time, of the intensity values of the zone, extracted from the images is obtained. These signals highlight the evolution of the contrast product injected into the area of the heart under study.
- This ratio k corresponds to the decay parameter of the reference function.
- the cardiac output is thus calculated from the value given to the decay parameter k, adjusted so that the reference function above best describes the evolution of the measured intensity values.
- the maximum S max of the signal can be defined, as well as the time T max corresponding.
- the signal can thus be normalized by the maximum Smax and recaled on the abscissa with respect to the corresponding time T max .
- a low pass filter can be applied to the curve of the contrast decay signal to smooth the curve.
- the decay parameter k is directly related to the volume / area of the cavity observed. If this volume is very large, there is an underestimation of the value of the parameter k thus measured calculated cardiac output.
- the value of the decay parameter k can be corrected by multiplying it by the ratio of the surface of the cavity to the average surface normally observed for this cavity.
- the average surface normally observed for the cavities can be obtained by averaging the surfaces obtained for a certain number of so-called standard patients according to the ultrasound recommendations.
- the method can thus include the step of determining the extent of the area of interest for measuring the intensity of the ultrasound signal and calculating the cardiac output taking into account this range, or by applying a patch for reduce the measured values to values comparable to those obtained for a reference area of reference, or by using different reference curves as a function of the extent of the area observed.
- a computer program product for the implementation of the cardiac output measuring method using an ultrasound apparatus as defined above, the computer program product comprising code instructions that, when executed by a processor, cause:
- a plurality of images of a region of the heart where a contrast agent was injected to is acquired by ultrasound apparatus, at different times,
- the cardiac output is calculated from the value given to at least one parameter of a reference function, adjusted so that said function best describes the evolution of the measured intensity values.
- the computer program product according to the invention can be integrated into an echocardiography device, in particular being recorded on an electronic card comprising a microprocessor integrated in the echocardiography apparatus.
- the computer program product is integrated with an external system.
- FIG. 1 represents the evolution over time of a temperature signal obtained by the thermodilution method of the prior art
- FIG. 2 illustrates steps of implementation of an exemplary method according to the invention
- FIG. 3 represents transoesophageal echocardiography images used for the implementation of the invention, with the contour of the area of interest materialized,
- FIG. 4 represents a device according to the prior art for producing the contrast product
- FIG. 5 represents a device according to the invention for producing the contrast product
- FIG. 6 illustrates the appearance of the contrast related to the use of the contrast product
- FIGS. 7A and 7B show timing diagrams of intensity value signals obtained by applying the method according to the invention
- FIG. 8A represents an example of a contrast evolution signal obtained according to the invention and adjusted
- FIGS. 9a to 9d illustrate another example of comparison of signals obtained according to the invention and according to the prior art
- FIGS. 10a and 10b show the decay signal of the intensity values obtained by applying a method according to the invention
- FIG. 11 represents another example of a decay signal, after normalization, and before and after filtering
- FIG. 12 illustrates the adjustment of the reference function to make it correspond to the decay curve of FIG. 11 after filtering
- FIG. 13 represents the correlation between the cardiac output measured by thermodilution and the decay parameter k
- FIG. 14 is a curve representing the cardiac output calculated as a function of the decay parameter k, for patients having a standard right atrium surface,
- FIG. 15 shows the inclusion on the curve of FIG. 14 of a patient having a dilated right atrium (area 28 cm 2 )
- Figure 16 represents the curve of Figure 15 with corr e cting decay parameter k.
- FIG. 2 shows various steps for implementing the method for measuring cardiac output of a heart according to the invention.
- the patient is prepared for echocardiography, to allow, among other things, the measurement of his cardiac output.
- a transesophageal echocardiography probe is used to obtain a visualization of the right atrium OD, as shown in FIG.
- one or more serum syringes for example five, containing 4 ml of saline and 0.5 ml of air, are prepared.
- the invention is not limited to a particular type of contrast product, even though a serum / air mixture is very largely preferred.
- the contrast product may be produced using the device as illustrated in FIG. 4, comprising two syringes 2 and 3, connected to a three-way valve 4.
- the serum contained in the first syringe 2 is propelled towards the second syringe 3 , empty, then reinjected into the first syringe 2 to obtain a homogeneous solution containing microbubbles of air.
- a device 10 according to the invention as shown in Figure 5 having a single syringe 5, connected to a valve 7 and an extension 6, to be connected to the injection catheter.
- the piston 5a of the syringe 5 can be actuated automatically several times in a row, by a mechanism not shown, by example ten times, to form air microbubbles. With each pull of the piston 5a, a depression is created in the syringe, then the piston 5a is released to break the vacuum.
- valve 7 is opened, and the serum containing the microbubbles of air is injected.
- Stage 12 in FIG. 2 corresponds to the injection of the contrast medium via a jugular vein catheter or via the injection route located on the Swan-Ganz introducer introducer valve.
- a recording of a plurality of images is made from the beginning of the injection until complete disappearance of the ultrasound contrast.
- An example of a contrast test according to the invention is shown in FIG.
- Each image is analyzed in terms of signal contrast by image analysis.
- the region of interest which is delimited by an oval contour in FIG. 3 is placed on the ultrasound images, as a function of the experimental conditions, in particular of the injection site. .
- the intensity of the ultrasound signal corresponds to the average of the gray levels of the pixels located in the region of interest.
- This signal A which corresponds to the arrival of the contrast product and then to its departure is modulated by the heartbeat.
- the envelope of the signal A is similar to the signal obtained by the thermodilution technique, represented in FIG. 1.
- the cardiac output is then calculated during a step 16.
- thermodilution method In order to compare with the thermodilution method, at least three syringes of 5 to 10 ml of microbubble solution were used, and the experiment was repeated with each of these syringes. The contents of each syringe are injected into the right atrium using a catheter. The thermodilution cardiac output is obtained with the temperature decrease curve, as previously stated.
- thermodilution signals can be adjusted by a reference curve, produced by a decreasing exponential and a power of time, as previously described.
- An example of adjustment is shown in Figure 8A by the dashed line.
- FIG. 9 shows a type of signal A from which the points of the envelope have been extracted and superimposed on the corresponding thermo dilution curve. The superposition is remarkable. This confirms the similarity between the curves obtained by the prior art and by the invention, and shows that the dispersion of a contrast product can serve as a basis for measuring the cardiac output.
- a second signal B represented in FIG. 7B, is obtained, where only the contrast decay is recorded.
- the decay is adjusted by an exponential equation, as previously described.
- An example of a signal B extracted from ultrasound images of a patient is shown in curve (a) of FIG. 10.
- the origin of the curve as abscissa is shifted, before adjustment by the reference function, after having determined the maximum of the signal S max and the corresponding time T max , as visible on the curve (b) of FIG. 10.
- the adjustment of the curve by a decreasing exponential function of the decay parameter k is satisfactory.
- a low-pass filtering of the contrast-decreasing signal B is carried out and leads to the curve (b) of FIG. 11.
- an adjustment by the reference function of the signal B is advantageously carried out, from the curve (b) of FIG. 11 in the example considered, as illustrated in FIG. 12.
- the best fit is sought while playing on the value of the parameter k, so that the reference function best describes the evolution of the intensity values measured.
- the correlation between the cardiac output and the decay parameter k is established from values of the parameter k whose flow rate measured in thermo dilution is known, as represented in FIG. 13. These preliminary results indicate an excellent correlation between the flow rate measured in thermo dilution and the parameter k measured according to the invention, with an error p less than 5.10 -4 .
- the curves of FIGS. 14 to 16 show examples of cardiac output calculated as a function of the decay parameter k, according to the size of the right atrium of the patient.
- Figure 14 corresponds to patients having a right atrial extent less than 18 cm 2 .
- the value obtained for a patient having a right atrium with an extent of 28 cm 2 was included on this curve in Figure 15.
- the decay parameter k is in this case overestimated.
- the decay parameter k is then advantageously corrected, for example by the ratio of the area of interest area observed to the average surface normally observed for this zone.
- the invention can be used on patients hospitalized in medical intensive care for a state of shock and / or respiratory distress.
- the measurement must be made after stabilization of the hemodynamic state, that is to say, it does not undergo a change in blood pressure, or heart rate, no therapeutic modification, no change in the respirator setting if necessary, for more than one hour.
- a transesophageal echocardiography probe can be put in place and the measurements made. The probe can be left in place to monitor the patient's hemodynamic status.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Acoustics & Sound (AREA)
- Physiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Databases & Information Systems (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1655360A FR3052351B1 (fr) | 2016-06-10 | 2016-06-10 | Procede de mesure du debit cardiaque par echographie |
PCT/EP2017/063718 WO2017211831A1 (fr) | 2016-06-10 | 2017-06-06 | Procede de mesure du debit cardiaque par echographie |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3468474A1 true EP3468474A1 (fr) | 2019-04-17 |
Family
ID=56842874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17727897.5A Withdrawn EP3468474A1 (fr) | 2016-06-10 | 2017-06-06 | Procede de mesure du debit cardiaque par echographie |
Country Status (7)
Country | Link |
---|---|
US (1) | US20190142364A1 (fr) |
EP (1) | EP3468474A1 (fr) |
JP (1) | JP2019517903A (fr) |
CN (1) | CN109414247A (fr) |
CA (1) | CA3027235A1 (fr) |
FR (1) | FR3052351B1 (fr) |
WO (1) | WO2017211831A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111939423B (zh) * | 2020-06-29 | 2022-07-12 | 杨铭轲 | 基于自体心跳节奏的入睡引导方法、装置和计算机设备 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0758251A1 (fr) | 1994-05-03 | 1997-02-19 | Molecular Biosystems, Inc. | Composition servant a mesurer le debit de perfusions myocardiques par ultrasons |
US5897851A (en) * | 1995-06-07 | 1999-04-27 | Sonus Pharmaceuticals, Inc. | Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging |
JP2006272232A (ja) * | 2005-03-30 | 2006-10-12 | Hitachi Ltd | 超微細気泡の生成方法、生成装置及びそれを利用した殺菌・消毒設備 |
CN202621350U (zh) * | 2012-06-21 | 2012-12-26 | 长沙有色冶金设计研究院有限公司 | 一种发泡枪 |
US20140275976A1 (en) * | 2013-03-15 | 2014-09-18 | Adventist Health System/Sunbelt, Inc. | Global Ventricular Cardiac Diastolic Function Evaluation System and Associated Methods |
-
2016
- 2016-06-10 FR FR1655360A patent/FR3052351B1/fr not_active Expired - Fee Related
-
2017
- 2017-06-06 WO PCT/EP2017/063718 patent/WO2017211831A1/fr unknown
- 2017-06-06 CN CN201780036067.2A patent/CN109414247A/zh active Pending
- 2017-06-06 CA CA3027235A patent/CA3027235A1/fr active Pending
- 2017-06-06 EP EP17727897.5A patent/EP3468474A1/fr not_active Withdrawn
- 2017-06-06 US US16/308,213 patent/US20190142364A1/en not_active Abandoned
- 2017-06-06 JP JP2019517150A patent/JP2019517903A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
FR3052351A1 (fr) | 2017-12-15 |
CA3027235A1 (fr) | 2017-12-14 |
WO2017211831A1 (fr) | 2017-12-14 |
CN109414247A (zh) | 2019-03-01 |
US20190142364A1 (en) | 2019-05-16 |
JP2019517903A (ja) | 2019-06-27 |
FR3052351B1 (fr) | 2021-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8861812B2 (en) | Ultrasonic imaging apparatus | |
US10448850B2 (en) | Photoacoustic flowmetry systems and methods | |
CN110367965A (zh) | 便捷测量冠状动脉血管评定参数的方法、装置及系统 | |
Pemberton et al. | Real-time 3-dimensional Doppler echocardiography for the assessment of stroke volume: an in vivo human study compared with standard 2-dimensional echocardiography | |
CN110522439A (zh) | 测量冠状动脉血管评定参数的简化方法、装置及系统 | |
WO2017211831A1 (fr) | Procede de mesure du debit cardiaque par echographie | |
FR2851449A1 (fr) | Microcapteur de pression arterielle et appareil de mesure l'utilisant | |
CA2948846C (fr) | Methode d'evaluation continue du couplage ventriculo-aortique de patients a risque, par analyse de boucles pression-flux | |
EP3052022B1 (fr) | Dispositif et procédé de mesure non invasive pour l'estimation de paramètres métaboliques locaux | |
CN107506791A (zh) | 一种对动脉粥样硬化斑块进行分类的系统 | |
Ho | Echocardiographic assessment of diastolic function | |
Tranquart et al. | Imagerie fonctionnelle de contraste | |
Möckel et al. | Continuous measurements of renal perfusion in pigs by means of intravascular Doppler | |
Nishimura et al. | Contemporary Reviews in Cardiovascular Medicine | |
WO2021019186A1 (fr) | Dispositif cardiaque | |
Akgun et al. | Discrepancies between Doppler and catheter gradients in ventricular septal defect: a correction of localized gradients from pressure recovery phenomenon | |
Malý et al. | Near-infrared spectrometry: the future of renal graft perfusion monitoring? | |
WO2007128518A1 (fr) | Procede et dispositif non-invasif de mesure en continu de la pression arterielle | |
TICKNER et al. | 28. DETERMINATION OF CARDIAC OUTPUT BY TWO-DIMENSIONAL CONTRAST ECHOCARDIOGRAPHY ANTHONY N. DEMARIA, WILLIAM BOMMER, JULIA RAZOR | |
Alegret et al. | Restrictive left ventricular filling and preserved ventricular function: a limitation in the noninvasive estimation of pulmonary wedge pressure by Doppler echocardiography | |
Santosa et al. | The utility of 3D left atrial volume and mitral flow velocities as guides for acute volume resuscitation | |
EP1493382A2 (fr) | Méthode et arrangements pour déterminer une courbe de dilution d'un indicateur dans le sang d'un humain ou d'un animal | |
Tweedie et al. | Direct arterial pressure measurements during operation to assess adequacy of arterial reconstruction in lower limb ischaemia | |
JP6596228B2 (ja) | 心臓カテーテル検査装置及び心臓カテーテル検査装置の作動方法 | |
Meekings | Monitoring Cardiac Output |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181128 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20211214 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20220625 |